Podcasts about teva pharmaceutical industries

In this episode, Ayesha spoke with Jeremy Levin, D. Phil, MB BChir, CEO and Chairman of Ovid Therapeutics Inc., and Meg Alexander, Chief Strategy Officer at Ovid.Ovid Therapeutics is a biopharmaceutical company focused on the development of medicines for epilepsies and seizure-related neurological disorders.Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries and a member of the executive committee at Bristol-Myers Squibb (BMS) Company where he was the architect, lead and implementer of the String of Pearls Strategy, which transformed BMS and facilitated the initiation and massive growth of the immuno-oncology revolution in the biopharmaceutical industry. Dr. Levin also serves on the board and executive committee of the Biotechnology Innovation Organization (BIO) as the immediate past chairman. Dr. Levin was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech, one of the top three biotechnology CEOs by The Healthcare Technology Report and one of the PharmaVoice100 CEOs in 2020 and 2021. He was selected by Endpoints in 2021 as one of the 60 living pioneers of the industry, and has received several awards throughout his career. Dr. Levin has practiced medicine at university hospitals in England, South Africa and Switzerland. Meg Alexander serves as Ovid's chief strategy officer, a role in which she oversees and supports the company's corporate strategy and planning, performance measurement and risk mitigation. She also oversees the company's corporate affairs function with a focus on engaging Ovid's stakeholders across patient and caregiver communities, policymakers, press and investors.Ms. Alexander has worked in the biopharmaceutical industry for two decades and has played a key role in launching more than 25 new medicines for many conditions including rare epilepsies, ALS, HIV, multiple sclerosis, Batten's disease, cardiovascular disease and cancer. She has advised and led campaigns for large healthcare organizations, including Pfizer, Novartis, Amgen, Eli Lilly, Nestle and Coca-Cola among many others. Prior to Ovid, she founded and led the Reputation & Risk Management Group, a consultancy within Syneos Health, one of the world's largest clinical research organizations. Ms. Alexander was named a “Disruptor” and a “Rising Star” in her industry by PM360 and the Healthcare Business Women's Association, respectively.This year, OVID is expecting several CNS data readouts, including one for its lead product candidate soticlestat, which is currently in Phase III trials for the treatment of refractory seizures in Lennox-Gastaut syndrome and Dravet syndrome, a rare epilepsy with high unmet need.Tune in to the episode to learn more about Ovid Therapeutics' developmental pipeline featuring treatments for epilepsies and seizures associated with rare brain conditions.  For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/  Follow Us on Social MediaTwitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

On this day in legal history, October 12, 1977, the US Supreme Court heard arguments in the landmark case of Allan Bakke, which centered around the contentious issue of "reverse discrimination." Bakke, a white student, had been denied admission to the University of California Davis Medical School, with the school reserving a specific number of seats for minority applicants. Bakke argued that this affirmative action policy amounted to racial discrimination against him. The case was seen as a significant challenge to affirmative action programs aimed at redressing past racial injustices.During the oral arguments, the justices grappled with the complex question of whether race-based admissions policies violated the equal protection clause of the Fourteenth Amendment. The case ultimately led to a divided decision. In 1978, the Supreme Court ruled in favor of Bakke, stating that while affirmative action was permissible, the use of racial quotas in admissions was unconstitutional. This decision had far-reaching implications for affirmative action policies in higher education and set a precedent for future legal battles on the issue.A divided en banc US appeals court has granted California's emergency stay of a lower court ruling that barred the state from enforcing its law limiting the capacity of gun magazines to 10 bullets or less. The US Court of Appeals for the Ninth Circuit voted 7-4, allowing most of the trial judge's order to be stayed, with the exception of magazines lawfully acquired and possessed before the judge's order granting a permanent injunction. The court stated that Attorney General Rob Bonta was likely to succeed on the merits, citing the 2021 US Supreme Court decision in New York State Rifle & Pistol Ass'n, Inc. v. Bruen, which limited the restrictions states can place on where gun owners can take their firearms. This majority decision noted that, since the Bruen decision, ten other federal district courts have considered Second Amendment challenges to large-capacity magazine restrictions, and only one court, the Southern District of Illinois, granted a preliminary injunction.The majority found that California demonstrated that it would face significant harm if the stay was denied, as it could lead to an influx of large-capacity magazines, posing potential threats to public safety. The ruling stated that other interested parties would not be substantially harmed by the stay, and it does not impede the public's ability to purchase and possess various firearms and magazines containing 10 rounds or fewer. This recent decision, while not deciding the case's merits, has temporarily stayed the injunction, allowing California to enforce its large-capacity magazine limit while the case proceeds. California High Capacity Gun Magazine Ban Mostly Unblocked (1)Anti-affirmative action activist Edward Blum's American Alliance for Equal Rights has dropped a lawsuit against Perkins Coie, a U.S. law firm, over its diversity fellowship program. The decision came after Perkins Coie revised its application criteria, allowing all law students to apply, not just those from "historically underrepresented" groups. Blum's group had initially sued two firms in August, alleging that their diversity fellowship programs unlawfully excluded individuals, including white students, based on their race. The move to open these programs to all students preempted further legal action, though Blum highlighted the existence of similar "racially discriminatory programs" at other law firms, encouraging them to do the same. Last year, major U.S. law firms had just 11.4% partners from people of color, according to the National Association for Law Placement.Affirmative action opponent drops case over law firm's diversity fellowship | ReutersPfizer has agreed to a $50 million settlement to resolve claims by drug wholesalers that they overpaid for EpiPen allergy treatment devices due to alleged anticompetitive practices by the drugmaker. The wholesalers argued that Pfizer, which manufactured the EpiPen for Mylan, engaged in anticompetitive behavior that allowed them to maintain a monopoly over the market for EpiPens, leading to inflated prices. This class action settlement, filed in a Kansas City, Kansas federal court, must still be approved by the judge.The legal action against Pfizer and Mylan followed public outrage in 2016 when Mylan raised the price of EpiPens from $100 to $600. The lawsuits claimed that the companies engaged in anticompetitive practices to stifle competition and maintain high profits, including paying Teva Pharmaceutical Industries to delay the launch of a generic version of the EpiPen. In 2021, U.S. District Judge Daniel Crabtree dismissed the claims against Pfizer on the grounds that it was Mylan, not Pfizer, that directly sold the EpiPen. In 2021 and 2022, groups of consumers reached settlements of $345 million and $264 million with Pfizer and Mylan, respectively, over related claims.Pfizer to pay $50 mln to settle drug wholesalers' EpiPen antitrust claims | Reuters Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

On this day in history August 28, 2003, the Supreme Court of Alabama removed a monument of the Ten Commandments from its courthouse. The Ten Commandments monument in the Alabama Supreme Court building was initially installed by Chief Justice Roy Moore, garnering support from evangelical Christians nationwide. However, Moore's refusal to comply with a federal court order to remove the monument by August 20 led to divisions among religious conservatives. Prominent figures like Pat Robertson criticized Moore for undermining the rule of law, while others like James Dobson praised him for prioritizing "God's law." Eventually, the monument was moved to a storage room, complying with the federal court order, but causing protests and prayers from demonstrators. The issue remained divisive, with Moore filing an appeal with the U.S. Supreme Court, even as eight of his state Supreme Court colleagues overruled him and ordered the monument's removal. Ultimately, the Supreme Court denied certiorari and the case died there–with the monument in a storage room and Roy Moore eyeing bigger things.Moore's bid for those bigger things – namely a special election to the Senate – would similarly end in failure. In 2017, in the midst of a campaign, Moore faced allegations of misconduct from multiple women. Some of these women allegedly claimed that Moore had assaulted them when they were minors and he was in his 30s. Moore denied all allegations and received varying levels of support from Republican figures, including an endorsement from President Donald Trump. Despite the allegations, Moore's name remained on the ballot, and he ultimately lost the election to Democratic candidate Doug Jones. Legal battles ensued, including defamation lawsuits from both Moore and one of the accusers, and as of August 2022, Moore was awarded $8.2 million in a defamation lawsuit, which is currently under appeal.The monument, as of 2020, was on display on private property in Montgomery, at Roy Moore's “Foundation for Moral Law” building. Millions of Americans struggling with ADHD medication shortages may find relief as U.S. regulators have approved a generic form of Vyvanse, a drug by Takeda Pharmaceuticals. This generic version could serve as an alternative to generic Adderall, which has been in short supply for a year. The approval is expected to bring financial relief to over one million Americans who use branded Vyvanse for ADHD or binge-eating disorder, as the cost of a 30-day supply has risen to $369. Fourteen companies are now authorized to manufacture and sell generic Vyvanse, according to the Food and Drug Administration.The shortage of generic Adderall began last August due to limited production at Teva Pharmaceutical Industries, its main manufacturer. This led many patients to switch to Vyvanse, although its availability was also affected by manufacturing issues. Until now, Vyvanse was only available as an expensive branded drug, making it unaffordable for some patients.David Goodman, a psychiatrist and assistant professor at the Johns Hopkins School of Medicine, noted that the main issue has been the cost. He has been switching some of his patients from Adderall to Vyvanse due to the shortage. The approval of generic Vyvanse is also expected to simplify the prescription process, as some insurance companies currently require special permission for Vyvanse coverage.Takeda Pharmaceuticals acquired Vyvanse in 2019 through its purchase of Shire Plc and has since tripled the drug's price. The company stated that its pricing aims to reflect the "value and innovation" of the treatments but did not comment on how the introduction of a generic version might affect prices.ADHD Drug Shortage Set to Ease as Generic Vyvanse Approved3M Co. has tentatively agreed to pay over $5.5 billion to settle more than 300,000 lawsuits alleging that it sold defective combat earplugs to the U.S. military. The settlement amount is significantly lower than the estimated $8-10 billion financial analysts had predicted the company might have to pay. This agreement comes after 3M's controversial attempt to limit its liability through a bankruptcy case, which ultimately failed. The company has lost 10 of 16 early trials over the earplugs, with over $250 million awarded to service members so far.The lawsuits claim that 3M knew its earplugs were too short to be effective and failed to warn the U.S. government or users. The settlement would be paid out over five years, pending approval from 3M's board. The company had tried to manage the litigation through its Aearo Technologies unit seeking Chapter 11 protection, but this move was criticized and eventually thrown out by a bankruptcy judge.The settlement would put an end to a significant portion of 3M's ongoing litigation, although the company still faces other lawsuits over PFAS "forever chemicals," which are likely to cost even more to resolve. In 2018, 3M agreed to pay $9.1 million to settle civil allegations by the U.S. Justice Department regarding the same earplugs. The company's shares rose by as much as 4% in pre-market trading following the news of the tentative settlement.3M Agrees to Pay More Than $5.5 Billion Over Military EarplugsTesla is facing its first trial over allegations that its Autopilot feature led to a fatal accident, marking a significant test for the company and its CEO, Elon Musk. The first trial, scheduled for mid-September in California, involves a 2019 crash where a Model 3 veered off a highway, hit a palm tree, and burst into flames, killing the owner and seriously injuring two passengers. A second trial in Florida in early October concerns another 2019 crash where a Model 3 drove under an 18-wheeler, resulting in the death of the owner. Both lawsuits accuse Tesla of knowing that its Autopilot system was defective.Tesla has denied liability, attributing the accidents to driver error and insisting that Autopilot is safe when properly monitored by humans. The company has previously won a case by arguing that its technology requires human monitoring, despite the names "Autopilot" and "Full Self-Driving."The upcoming trials could reveal new evidence about what Musk and Tesla officials knew regarding Autopilot's capabilities and limitations. Internal emails have been cited to argue that Musk is the "de facto leader" of the Autopilot team. Tesla has not commented on the trials but has been transparent about Musk's involvement in self-driving technology.Legal experts suggest that wins for Tesla could bolster confidence and sales for its software, which costs up to $15,000 per vehicle. However, losses, especially with large damage awards, could significantly impact the company's narrative and financial future.The stakes are particularly high for Tesla as these are the first trials involving fatalities linked to Autopilot. Court documents have also indicated that both sides are aware of the system's shortcomings, and punitive damages are being considered in the Florida case. Tesla has filed an emergency motion to keep deposition transcripts and other documents secret, a move that is being opposed by the plaintiffs.Focus: Tesla braces for its first trial involving Autopilot fatality | ReutersLawyers for Wall Street Journal reporter Evan Gershkovich have appealed a Moscow court's decision to extend his pretrial detention until November 30. Gershkovich, a 31-year-old U.S. citizen, was arrested on March 29 while on a reporting assignment in Russia. He is accused of espionage by Russia's Federal Security Service, a charge that both he and the Wall Street Journal, as well as the U.S. government, strongly deny. If the extension holds, Gershkovich will have been in detention for at least eight months before any trial begins, although a trial date has not yet been set. Previous requests by Gershkovich's lawyers for bail or house arrest have been denied. Gershkovich is the first American journalist to be arrested on espionage charges in Russia since the end of the Cold War. The U.S. State Department has labeled him as wrongfully detained and is exerting pressure on Russia for his release.Lawyers for Evan Gershkovich Appeal Extension of Pretrial Detention - WSJGeorgia Republicans are planning to use a new law to remove Fulton County District Attorney Fani Willis, who recently indicted former President Donald Trump for attempting to overturn the 2020 election results in Georgia. The law, signed by Republican Governor Brian Kemp in May, allows a commission of political appointees to remove elected prosecutors for various reasons, including not prosecuting certain offenses. State Sen. Clint Dixon accused Willis of using the justice system against political opponents and aiming to become a "leftist celebrity." The Public Rights Project, a nonprofit, has filed a preliminary injunction to halt any disciplinary or removal proceedings against prosecutors while litigation over the law is ongoing.The new law is part of a larger trend across the U.S., where nearly 40 similar measures have been introduced in a third of states since 2017. These laws often target prosecutors who are implementing criminal justice reforms and are usually driven by white Republican lawmakers against Black Democrats in cities. The law has already had a chilling effect on prosecutors across Georgia, making them hesitant to discuss their work or pursue reforms for fear of being targeted for removal.Georgia GOP Gears Up to Remove Atlanta Prosecutor Who Indicted Donald Trump Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

In der Rubrik “Investments & Exits” begrüßen wir heute Niklas Raberg, Investment Manager bei Capnamic. Niklas bespricht die Runde von Qualifyze.Das Frankfurter Startup Qualifyze, das Pharmafirmen in der Compliance-Sicherung unterstützt, hat in einer Finanzierungsrunde 12 Millionen US-Dollar eingesammelt. Investoren wie das Mailänder Family Office H14 SpA, HarbourVest Partners und HV Capital beteiligten sich. Qualifyze plant, die Lieferketten-Compliance im Gesundheitswesen mithilfe der Finanzierung zu stärken. Die Datenbank des Unternehmens umfasst Angaben von über 2.000 Pharma-Lieferanten, darunter Merck KGaA, Teva Pharmaceutical Industries und Sanofi SA. Ziel ist eine Umsatzverdopplung auf 10 Millionen Dollar in diesem Jahr aufgrund der steigenden Nachfrage nach Cloud-basierten Compliance-Datendiensten.

Avraham Hermon is a Senior Partner at JMB Davis Ben-David, a US Patent Agent and an Israel Patent Attorney. He has a BA in Chemistry and a Master's in Law. Prior to joining the firm Avraham worked in a number of Israeli pharmaceutical companies including Teva Pharmaceutical Industries where he led a team of patent attorneys in providing opinion on potential new developments and prosecuting patent portfolios related to Teva's products. Barak Hullman, the marketing director at JMB David Ben-David sat down with Avraham in his office to discuss what he's learned from interviewing over 20 Israeli startup founders, how patents help startups and when to pursue a patent, when to bootstrap and when to seek funding, why Israeli startups are so successful and much more. Do you have a great innovation? We'd love to hear from you. Contact us by going to https://jmbdavis.com/startup/contact. Learn more at https://jmbdavis.com and https://jmbdavis.com/startup. Also available at https://soundcloud.com/jmbdavis/avraham-hermon. Listen to all of the episodes at https://jmbdavis.com/podcast.

New York state's health commissioner declared monkeypox an "imminent threat to public health" on Thursday amid a rapid increase in cases. A newly unveiled FBI search warrant shows that the man accused of attempting to assassinate Supreme Court Justice Brett Kavanaugh meticulously planned the alleged plot and even reached out for advice on an internet forum. Another set of human remains was found at Lake Mead Monday as the reservoir's water levels continue to recede, according to a news release from the National Park Service. Clean energy advocates, solar workers, and community leaders are speaking out against a proposal that would raise solar energy costs. A big pink diamond of 170 carats has been discovered in Angola and is claimed to be the largest such gemstone found in 300 years. California Attorney General Rob Bonta announced Tuesday that 12 states have negotiated a tentative $4.25 billion settlement with opioid manufacturer Teva Pharmaceutical Industries over its marketing and distribution of potent and addictive painkillers.See omnystudio.com/listener for privacy information.

On February 25, 2022, Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., McKesson Corp., Cardinal Health, Inc., and Amerisourcebergen Corp. announced that they had agreed to finalize a reported $26 billion settlement to resolve approximately 3,000 lawsuits from state and local governments regarding the opioid abuse crisis. The private plaintiffs' trial firms representing the counties and […]

On February 25, 2022, Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., McKesson Corp., Cardinal Health, Inc., and Amerisourcebergen Corp. announced that they had agreed to finalize a reported $26 billion settlement to resolve approximately 3,000 lawsuits from state and local governments regarding the opioid abuse crisis. The private plaintiffs' trial firms representing the counties and […]

On February 25, 2022, Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., McKesson Corp., Cardinal Health, Inc., and Amerisourcebergen Corp. announced that they had agreed to finalize a reported $26 billion settlement to resolve approximately 3,000 lawsuits from state and local governments regarding the opioid abuse crisis. The private plaintiffs' trial firms representing the counties and municipalities filed the first lawsuit in California in 2014. The proposed settlement allocates approximately $2.3 billion for the plaintiffs' attorneys' fees and costs. The most controversial legal issue was whether the defendants' marketing created a “public nuisance.” The companies continue to face claims in Alabama, Washington, West Virginia and Oklahoma, where in November 2021 the Oklahoma Supreme Court ruled that the state's public nuisance statute did not extend to the manufacturing, marketing, and selling of prescription opioids. On November 23, 2021, an Ohio federal jury found CVS, Walgreens, and Walmart pharmacies liable for recklessly distributing opioids in Lake and Trumbull counties in Ohio. Rite Aid and Giant Eagle settled in 2021. U.S. District Court Judge Dan Polster is scheduled to decide damages this spring. Please join us on Tuesday, March 8, 2022, at 2:00pm EST/11:00am PST, as John Shu, who has been following the national litigations, will hold a Zoom webinar to update us on the litigations in California, Oklahoma, and Ohio, and discuss their legal and strategic issues. Featuring:-- John Shu, Professor, Attorney, and Legal Commentator

Keren Haruvi is President of Sandoz US and Head of their North America business (https://www.novartis.us/about-us/our-leadership/us-country-leadership/keren-haruvi). Sandoz is a division of the Novartis Group and a global leader in generic pharmaceuticals and biosimilars and was established in 2003, when Novartis united all of its generics businesses under the name Sandoz – a single global brand with a long history. Since then, Sandoz has grown into a leading global generics business with annual sales of approximately US$10 billion. In her current role, Keren leads Sandoz' largest commercial and country organization – the United States – which is responsible for over 35% of Sandoz global revenue. She also oversees Sandoz commercial operations in Canada. In addition to serving on the Novartis Country Leadership Team, Keren is a member of the Global Sandoz Executive Committee. Prior to joining Sandoz, Keren served as Global Head of M&A at Novartis International AG. Her early career began at Teva Pharmaceutical Industries where she steadily advanced in leadership roles to Senior VP, Global Business Development and Alliance Management. Keren is a value creator in the biopharmaceutical space, and brings close to 20 years of experience in the pharmaceutical industry, marked by success leading major M&A deals, enterprise innovations, and complex market strategies for large-scale, sustainable growth. Keren holds an MBA in Finance from Bar Ilan University and a Bachelor's degrees in Economics and Chemistry from Tel Aviv University. Nominated for Top 40 Under 40 in The Marker magazine, she exemplifies the insight and wisdom needed to move global organizations forward. Outside of work, Keren enjoys spending time with her 5 children. She is an avid runner with one marathon and 3 half-marathons under her belt.

True Pundit: EXCLUSIVE: TOP Scientist & HIV/AIDS Research Pioneer Dr. Judy Mikovits Blows Whistle on Dr. Fauci; DISTURBING Details of Threats; Research Theft; Tainted Vaccines; Fraud; Cover-Ups; Pay to Play https://truepundit.com/exclusive-top-scientist-disturbing-details-of-threats-research-theft-tainted-vaccines-fraud-cover-ups-pay-to-play/ The Bill & Melinda Gates Foundation pledged US$ 750 million to set up Gavi in 1999 in order to drive toward mandatory vaccines worldwide. The Office of the Assistant Secretary for Health issued new guidance under the Public Readiness and Emergency Preparedness Act authorizing licensed pharmacists to order and administer COVID-19 tests that the U.S. Food and Drug Administration has authorized. https://www.hhs.gov/about/news/2020/04/08/hhs-statements-on-authorizing-licensed-pharmacists-to-order-and-administer-covid-19-tests.html Townhall: Israeli Professor Yitzhak Ben Israel of Tel Aviv University, who also serves on the research and development advisory board for Teva Pharmaceutical Industries, shows The Wuhan Virus follows its own fixed pattern that is not dependent on freedom or quarantine. “There is a decline in the number of infections even [in countries] without closures, and it is similar to the countries with closures,” https://townhall.com/columnists/marinamedvin/2020/04/15/israeli-professor-shows-virus-follows-fixed-pattern-n2566915 Tune in Monday through Friday at 11:00am EDT for another show. Visit our sister website, http://www.theprayerfulpatriot.com dedicated to faith and prayer. https://www.patreon.com/jeromecorsi/ https://www.subscribestar.com/jerome_corsi/

Listen to this episode at Team Coaching Zone https://www.teamcoachingzone.com/, on iTunes, SoundCloud, Spotify, or anywhere you listen to podcasts. This week on the show, Nicholas Janni, transformational coach, leadership development specialist and founder of Core Presence joins me Carissa Bub as we talk how we tend to live in a world of absence, what happens when you combine being and doing, and how developing presence can transform teams and organisations. Nicholas and I discuss: His childhood discovery aged 16 that inspires his work What led him to theatre as a spiritual practice The work and his experience as a co-founder of Olivier Mythodrama What he means by presence and how he defines leadership presence What it takes to help leaders and teams shift their concept of reality How he works with teams His work at IMD in preparing leaders for the future His vision for cultures of presence More on Nicholas: Over the last 15 years Nicholas has gained an international reputation for his transformational coaching and leadership development seminars for leaders and teams. The clients he has served include FedEx, Rolls Royce, Swiss Re, Centrica, Teva Pharmaceutical Industries, Amdocs, Intel, Motorola, Microsoft, eBay and Lafarge, as well as the UK Permanent Secretaries and several cabinet ministers. He bridges the worlds of creative, personal, spiritual and professional development in a uniquely powerful, relevant and accessible way. In his first career Nicholas was a theatre director. He taught acting at The Royal Academy of Dramatic Art in London, and directed his own theatre company. He has spent 30 years researching the theory and the practice of ‘the zone’ of peak performance, and studying multiple mind/body disciplines. In 1998 he became a Visiting Fellow at the Cranfield School of Management, and in 2001 he left the theatre to co-found the arts-based leadership development consultancy Olivier Mythodrama. In 2013 he founded his own consultancy, CORE PRESENCE. He was an Associate Fellow at the University of Oxford Said Business School 2010–15, and currently teaches regularly at the IMD Business School in Lausanne where he leads large international groups. He is based partly in Israel, where he works with numerous corporate clients, Israeli and Palestinian NGO’s and at Tel Aviv University Recanati Business School. You can find everything you want to now about Nicholas here: https://www.nicholasjanni.com P.S Whenever you’re ready . . . here are 4 ways I and Team Coaching Zone can help inspire your imagination and impact:   1) Join the Community of Change Makers:  For the past few years we’ve been developing a community of change makers. Entrepreneurs and coaches who want to impact people and the planet in new and innovative ways. We are a supportive group committed to deepening our missions and lifting each other up when things get tough. If you'd like to learn more, go to: https://www.teamcoachingzone.com/community/ 2) Join a Master-class or Webinar: If you're looking for more imagination, tools and courage to take your coaching practice to the next level we have a menu of learning bites to inform and entertain you. You can attend a masterclass or log in and join a growing number of our live webinar series we are launching around the world. Check out https://www.teamcoachingzone.com/team-coaching-master-classes  for more information. 3) Nautilus Experience: Come on an Adventure of a Lifetime Every year, we take a group of coaches on a once-in-a-lifetime adventure. I believe that adventuring gets us out of our comfort zone, stimulates us in new ways and helps us connect with the world around us. These trips are designed to disrupt your current reality, challenge your assumptions and reconnect you to your wider purpose. This year we were in Norway on the Nautilus Voyage learning to sail and experimenting with team of teams. Join us in 2020 in Cuba in April or in Arctic Norway in July for our next adventure! For more information go to: https://www.teamcoachingzone.com/nautilus 

Whether you’re dealing with medical devices or new drugs–regardless if it’s a product or a service, and whether that product or service ever even leaves the United States, export controls affect every organization in one way or another. That’s why I was so excited to sit down with Export Controls and Compliance expert, Wendy Epley, the president of Epley Consulting, for this episode of Compliance Conversations. As a compliance professional in healthcare, you might hear the word “export” and think ‘I don’t ship anything out of the country, so export controls don’t apply to me.’ But surprisingly it does! Epley explained, “[export controls] is referring to a very complicated network of federal agencies and regulations that are interconnected to regulate or control how things are to be protected in order that they are not used in a way that would cause harm...regardless of where those persons are located, including if they are here within the United States.” Epley also went into detail about the foreign corrupt practices act, an important act for many of you in various healthcare compliance roles. “Just a few years ago, Teva Pharmaceutical Industries paid nearly five hundred and twenty million...for its role in violations with the FCPA.” Said Epley. Find out how export controls apply to all of you healthcare compliance professionals out there. Tune in to my latest episode of Compliance Conversations, Export Controls: The Most Important Compliance Element You Probably Haven’t Heard Of, to learn why: One Doctor Went to Prison For His Research Some Medical Equipment and New Drugs Pose A Risk You Need to Institute Export Protocols and Training in a Research Uni Setting Teva Pharmaceutical Industries Paid Nearly $520 Million in Violations

In this episode, we speak with Lynn Julian, a musician, actress, marathon runner and advocate. Lynn shares her lifelong journey living with an invisible illness from concussions and chronic pain in her early life to traumatic brain injury after the devastating 2013 Boston Marathon bombing. Despite her injuries, perseverance, hard work, and proper diagnosis have led her to advocacy and a purpose through the pain. This podcast is sponsored in part by Amgen/Novartis, Alder BioPharmaceuticals and Teva Pharmaceutical Industries. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we will hear from Dr. Michael Teixido, a neurotologist who specializes in conditions that affect hearing and balance. Dr. Teixido explains the pathophysiology of the different types of migraine, as well as the various symptoms associated with each disorder. Dr. Teixido explains common and rare migraine disorders including familial hemiplegic migraine, migraine with aura, abdominal migraine, precordial migraine and more. This podcast is sponsored in part by Amgen/Novartis, Alder BioPharmaceuticals and Teva Pharmaceutical Industries. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, Alene Brennan, a nutrition coach, yoga instructor and chef shares natural remedies to help people with migraine reach their optimal health. Alene explains some best practices for incorporating essential oils into a migraine management regimen, including their use for children. This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries.  *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

Goodwin's Chairman David Hashmall interviews David M. Stark, Executive Vice President and Chief Legal Officer of Teva Pharmaceutical Industries, the world's largest generic drug company. Mr. Stark discusses his role, the evolving relationship between clients and their law firms, the importance of diversity and inclusion in the legal industry, and more. Mr. Stark became Executive Vice President, Chief Legal Officer of Teva in November 2017. From November 2016 to November 2017, he served as Group Executive Vice President, Chief Legal Officer. From 2014 to 2015, Mr. Stark was Senior Vice President and General Counsel, Global Specialty Medicines. Since joining Teva in 2002, Mr. Stark served in a series of roles with increasing responsibilities in Teva North America and Teva Americas, including as Senior Director, Deputy General Counsel, and Vice President and General Counsel. Prior to joining Teva, Mr. Stark was an associate attorney in the litigation departments at Willkie Farr & Gallagher LLP between 1998 and 2002, Chadbourne & Parke between 1997 and 1998 and Haight, Gardner, Poor & Havens between 1994 and 1997. Mr. Stark received a J.D. from New York University School of Law and a B.A. in political science from Northeastern University, summa cum laude.

Bob Bratzler, Ph.D. talks about a potential migraine treatment that was actually discovered by chance. Surprisingly, the use of a particular glaucoma medication was bringing headache relief to some patients who had migraine disease as well. This medication contains prostaglandins... The interesting thing is that prostaglandins are usually associated with causing pain, not preventing it... This medication is now undergoing a clinical trial for use as a migraine preventive treatment. This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries.  *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

Dr. Shivang Joshi of the Dent Neurologic Institute gives a presentation on the use of Marijuana or Cannabis for treating migraine and cluster diseases.  He touches on a bit of the pharmacology, the history of its use, adverse effects, who uses it, what studies have shown, and legal implications, dosing and more. This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

Neurologist Dr. Stewart Tepper explains how the new, "designer" CGRP blocking migraine treatments work, how they are delivered and what to expect for efficacy. Dr. Tepper's presentation was recorded in June 2018, after the first of these medications became available to patients in the U.S.   This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries.  *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The Association of Migraine Disorders does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

1) Featured Article: Collateral response modulates the time–penumbra relationship in proximal arterial occlusions2) Lesson of the Week: Migraine and neuromodulationThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 23, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Smriti Agarwal about her paper on collateral circulation in proximal arterial occlusions and extending the scope of thrombolytic therapy. In the second part of the podcast, Dr. Teshamae Monteith focuses her Lesson of the Week interview with Dr. Stewart Tepper on acute and preventative neuromodulation treatment for migraine. DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and Neurohospitalist; has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials; and receives publishing royalties from Wiley Blackwell.Dr. Agarwal reports no disclosures.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Tepper is a member of the board for the American Headache Society and has been a consultant for or participated on a paid advisory board for Acorda Therapeutics, Inc; Alder BioPharmaceuticals, Inc; Allergan plc; Amgen, Inc; Avanir Pharmaceuticals, Inc; BioVision, Inc; Charleston Laboratories, Inc; Dr. Reddy’s Laboratories, Ltd; electroCore, LLC; eNeura, Inc; Eli Lilly and Company; GLG Pharma, LLC; Guidepoint Inc, LLC, Ltd; Kimberly-Clark Corporation; Pernix Therapeutics Holdings, Inc; Pfizer, Inc; Scion NeuroStim, LLC; Teva Pharmaceutical Industries, Ltd; and Zosano Pharma, Corp.

The Philanthropy Episode – A Holiday Double Feature A CEO’s Virtual Mentor® Episode 14 Holiday greetings from The Leadership Lyceum!  Welcome to our 14th episode of the podcast. ‘Tis the season of giving and we give you our holiday gift in the form of this holiday special double episode on Philanthropy.  We’ll cover the subject from a few different angles. First. from the perspective of the giver – with our first guest, University of Chicago benefactor Bernard DelGiorno.  Bernie also advises his clients on charitable giving in his role in private wealth management at UBS. Next, from the angle of the recipient.  We’ll glean the perspectives of Jennifer Sampson, CEO of The United Way of Metropolitan Dallas.  Jennifer led a remarkable turnaround in Dallas and has led the development of programs that fund impactful and innovative social entrepreneurship.  Finally, we introduce you to a group of public company CEO’s in Ohio that are leveraging their musical talents to raise money for charities in Ohio.  Two of the CEOs that we feature have the ultra-cool distinction of being board members of the Rock and Roll Hall of Fame.  We feature the music of the CEO band, Power Chords throughout the music interludes in the program.  Segment I: Bernard DelGiorno, University of Chicago benefactor Segment II: Jennifer Sampson, CEO of the United Way of Metropolitan Dallas Segment III: The Ohio CEO band for charity - The Power Chords.  Perhaps it is not widely known that there is a group of several CEOs in Ohio have given their musical talent and time to charitable fundraising events.  One band that raises money for the Rock and Roll Hall of Fame includes three of the Rock and Roll Hall of Fame board members: Drums: Nick Akins, CEO of utility AEP in Columbus; Guitars, vocals and keyboards: George Barrett, CEO of Cardinal Health; Guitars: Dr. Michael Drake, President of The Ohio State University and; Bass: Greg Harris, President of the Rock and Roll Hall of Fame.  Another band, The Power Chords, includes Akins and Barrett, plus multi-instrument virtuoso and vocalist Joe Hamrock, the CEO of utility NiSource.  Segment III is my coverage of The Power Chords at their Thursday, September 28th evening gig fundraiser for the Mid-Ohio Foodbank in Grove City, Ohio, outside Columbus. Conclusion  We hope you enjoyed this holiday season episode of A CEO’s Virtual Mentor and the fitting subject of Philanthropy from its many different angles.  It’s clear across all of these segments the devotion of our guests to something larger than themselves.  Famous Last Words We close our episode in Lyceum tradition with Famous Last Words.  It’s December 24, 1941.  Christmas Eve.  Just 17 days after the Japanese attack on Pearl Harbor.  President Franklin D. Roosevelt lights the White House Christmas tree and is joined in this, his 9th ceremonial act (pre-presidential term-limits) by Prime Minister Winston Churchill, who was in Washington for the Arcadia Conference, the first wartime conference between these two close allies since the US entrance into World War II just 16 days prior on December 8th. Try as I might to edit this down for our 21st Century attention spans and our improved discourse efficiency at between 140 to 280 characters, with the fate of the world hanging in the balance, I lacked the courage to cut.  Use a bookmark, because it’s well worth a listen.  On this day, 76 years ago, two of the 20th century’s most monumental figures took the stage with two purposes.  On the surface, they took to the microphone to announce the lighting of a tree.  But in their soaring speeches, they made clear the principles for which they had now committed both of their nations.  The overtones and undertones are thought-provoking and revealing for our current state of sensibility.  Warm wishes for the holidays and for your resolve for the New Year. Thanks for joining us.  We can’t improve without your feedback – write us through our website www.LeadershipLyceum.com and subscribe on iTunes.  See you next time. Program Guide Episode 14 The Philanthropy Episode   0:19        Introduction 0:29        Introduction to specific programming in this Episode 14 2:38        Segment I: Bernard DelGiorno, University of Chicago Benefactor 23:05      Segment II: Jennifer Sampson, CEO of The United Way of Metropolitan Dallas 53:20      Segment III: The Power Chords, Benefit Concert 54:18      Nick Akins CEO of AEP 57:19      Matt Habash, CEO of Mid-Ohio Foodbank 1:04:26   Nick Akins CEO of AEP 1:08:03   George Barrett, CEO of Cardinal Health 1:12:12   Joe Hamrock CEO of NiSource 1:13:04   Nick Akins CEO of AEP & Joe Hamrock CEO of NiSource 1:22:42   Conclusion and Famous Last Words with Franklin Roosevelt and Winston Churchill (Christmas 1941).    Informative and Helpful Links  Our Sponsor – TransparentCareer https://www.transparentcareer.com   Board Game: Tesla vs Edison War of Currents To ensure pre-Christmas arrival, order your game now through Amazon at www.artana.com/store   Segment I – The Benefactor – Mr. Bernard DelGiorno Article on University of Chicago Alumni Service Medal Award Recipient: http://www.kintera.org/site/c.fnKDIQNsEkG/b.5179039/k.9C22/Bernard_DelGiorno.htm   Segment II – The Recipient – Jennifer Sampson, CEO of the United Way of Metropolitan Dallas https://unitedwaydallas.org/   Segment III – Giving Charitable Talents – Ohio's Rock and Roll CEOs The Rock and Roll Hall of Fame CEO Band: http://www.shadowboxlive.org/shows/are-you-ready-to-rock The Power Chords: https://aepretirees.com/2012/10/08/harvest-palooza-raises-50000-to-fight-hunger/ Rock and Roll Hall of Fame: https://www.rockhall.com   Famous Last Words Historical Background on the Darkest Days of World War II – 17 days after Pearl Harbor – FDR and Churchill Together in Washington Christmas Tree Lighting Ceremony http://www.smithsonianmag.com/history/darkest-days-world-war-ii-winston-churchills-visit-white-house-brought-hope-washington-180961798/   The Full Audio of FDR and Churchill’s Speeches on December 24th 1941 Christmas Tree Lighting Ceremony in Washington https://archive.org/details/PresidentFranklinRoosevelt411224WhiteHouseChristmasTreeCeremony   Biographies of Guests    Mr. Bernard DelGiorno Donor profile from the University of Chicago Alumni & Friends online community: http://www.kintera.org/site/c.fnKDIQNsEkG/b.5179039/k.9C22/Bernard_DelGiorno.htm   Ms. Jennifer Sampson Ms. Jennifer Sampson has been Chief Executive Officer and President of United Way of Metropolitan Dallas since September 13, 2011. Ms. Sampson served as an Executive Vice President and Chief Operating Officer at United Way of Metropolitan Dallas Inc. since 2004. Ms. Sampson serves as a Member of Customer Advisory Board at Atmos Energy Corp.   Mr. Nick Akins Nick Akins is chairman, president and chief executive officer of American Electric Power. He is AEP’s 11th chairman, 10th president and sixth CEO in the company’s more than 100-year history. He is a member of AEP’s board of directors and is the only management representative on the board. Akins rose through the ranks at both AEP and the former Central and South West Corp. (CSW), which merged with AEP in 2000. Akins began his career in 1982 as an electrical engineer before moving up to positions of increasing responsibility. Prior to being elected president of AEP in December 2010, he served as executive vice president - Generation from 2006 through 2010 with responsibility for all generation activities of AEP’s approximately 38,000 MW of generation resources. Previously, he served as president and chief operating officer for Southwestern Electric Power Company, and held other leadership roles in Energy Marketing Services, Transmission, External Affairs and Industry Restructuring. A native of Louisiana, Akins received his bachelor’s degree in 1982 in electric engineering from Louisiana Tech University in Ruston and a master’s degree in electrical engineering in 1986 from Louisiana Tech. Additional training includes executive management programs at Louisiana State University, the University of Idaho and the Reactor Technology Course for Utility Executives at the Massachusetts Institute of Technology. He is a registered professional engineer in Texas. Akins is a former chairman of the Board of Directors of both the Edison Electric Institute (EEI) and the Electric Power Research Institute (EPRI), and currently serves on both boards. He is a member of the Executive Committee of the Business Roundtable (BRT) and was appointed chair of the BRT's Energy and Environment Committee. Additionally, he is a member of the boards of the Nuclear Energy Institute (NEI), Global Sustainable Electricity Partnership (GSEP), The Columbus Partnership, Columbus Downtown Development Corporation, Nuclear Electric Insurance Limited (NEIL), Fifth Third Bancorp, OhioHealth and the Rock and Roll Hall of Fame and Museum. Akins and his wife, Donna, live in Dublin, Ohio. They have two adult sons.   Matt Habash, CEO of Mid-Ohio Foodbank Matt Habash became executive director of Mid-Ohio Foodbank in 1984.  Prior to that, Matt was with the St. Stephen’s Community House, first as a youth worker and then as the assistant to the executive director.  Matt also was a member of Columbus City Council from 1993 to 2006, serving as Council President from 1999 to 2006. As Council President, Matt governed with civility and humanity.  Co-Chair with Columbus Mayor Michael B. Coleman, Matt led the 21st Century Growth initiative, a plan designed to balance job creation with sustainable neighborhood development.  Other efforts spearheaded by Matt in his role as Council President was the 315 Research Corridor, the City’s Indoor Clean Air Act and the City’s Bike Path Plan.  He holds a Masters of Business Administration from Xavier University, a Masters of Public Policy from The Ohio State University, and a Bachelor of Arts in philosophy from Xavier University. Matt takes an active leadership role in the community, having served on numerous boards and has received numerous awards, recognizing his commitment and work in serving those most vulnerable.   Mr. Joe Hamrock Joe Hamrock serves as NiSource President and Chief Executive Officer. He has been in this role since July 1, 2015, and is also a member of the NiSource Board of Directors. Joe previously served as Executive Vice President and Group CEO for NiSource's Gas Distribution segment, which included local gas distribution companies in Kentucky, Maryland, Massachusetts, Ohio, Pennsylvania and Virginia. In that role, he was responsible for all financial, operational, regulatory and commercial performance at NiSource's gas distribution operations. In coordination with leadership teams across each of these areas, he focused on driving the company's long-term growth plan, premised on executing a steady stream of infrastructure improvements and growth investments, synchronized with complementary regulatory and customer program initiatives. Joe joined NiSource in May 2012 after serving in a variety of senior executive positions with American Electric Power (AEP), including President and Chief Operating Officer of AEP Ohio, and roles in engineering, transmission and distribution operations, customer service, marketing and information technology. He began his energy industry career as an electrical engineer in transmission and distribution planning at AEP in Steubenville, Ohio. He went on to work in commercial and industrial customer services, and held leadership roles in commercial marketing and customer services, strategic development and other executive roles. Prior to becoming President of AEP Ohio, Joe was Senior Vice President and Chief Information Officer in AEP's Shared Services organization from 2003-2007, and from 2002 to 2003 was Senior Vice President - General Services. Joe serves on the boards of the American Gas Association, Columbus Downtown Development Corp., the Columbus Partnership, the Greater Columbus Sports Commission and OhioHealth. He holds a bachelor's degree in electrical engineering from Youngstown State University and a master's degree in business administration from the Massachusetts Institute of Technology, where he was a Sloan fellow.   Mr. George Barrett George S. Barrett is chairman and chief executive officer of Cardinal Health, a company ranked among the top 25 on the Fortune 500 and dedicated to improving the cost-effectiveness of health care. Barrett has refocused Cardinal Health on its essential role in supporting hospitals, pharmacies and alternative sites of care in their efforts to improve the quality and safety of patient care, while reducing costs and improving efficiency.  The tagline – Essential to care – embodies the company’s strategy and the culture of the organization. Barrett has been chairman and CEO of Cardinal Health since 2009.  He joined the company in 2008 as vice chairman and CEO of the company’s Healthcare Supply Chain Services. From 2005 to end-2007, Barrett served as president and CEO of North America for Teva Pharmaceutical Industries.  During 2007, he also served as corporate executive vice president for Global Pharmaceutical Markets.  He held the position of president of Teva USA from 1999 to end-2004. Prior to joining Teva, Barrett held various positions with Alpharma Inc., serving as president of US Pharmaceuticals from 1994 to 1997, and president of NMC Laboratories, prior to its acquisition by Alpharma in 1990.  Barrett serves on the board of directors of the Federal Reserve Bank of Cleveland, Nationwide Children’s Hospital and the board of trustees of the Corporation of Brown University. He is a member of the Healthcare Leadership Council and The Conference Board. He is also a member of the Business Roundtable, The Business Council and The Columbus Partnership. Barrett also serves on the board of directors of the Rock and Roll Hall of Fame. Barrett earned his Bachelor of Arts degree from Brown University and a Master of Business Administration from New York University.  He also holds an Honorary Doctor of Humane Letters degree from Long Island University’s Arnold & Marie Schwartz College of Pharmacy and Health Sciences.   Subscribe to the podcast at iTunes: https://t.co/a70rtSiQnW or SoundCloud: https://soundcloud.com/thomas-linquist Follow Leadership Lyceum on:          Our website: www.LeadershipLyceum.com          LinkedIn: https://www.linkedin.com/in/thomas-linquist-682997          Twitter: @LeaderLyceum https://twitter.com/LeaderLyceum          Email us: info@LeadershipLyceum.com Please subscribe to the Leadership Lyceum: A CEO’s Virtual Mentor® at iTunes which will enable future content to come to you automatically.  Rate us and spread the word among your fellow executives and board colleagues.  Your host Thomas B. Linquist is the Founder and Managing Partner of Lyceum Leadership Consulting and Lyceum Leadership Productions. Over his 15 years in management and leadership consulting he has served a wide array of industrial clients.  This includes leadership assessment and search for chief executive officers, chief financial officers, chief operating officers and boards of directors.  He holds an MBA from the University of Chicago and over his 25-year career has served in a variety of roles: as an engineer with Shell Oil Company, a banker with ABN AMRO Bank, and as treasurer was the youngest corporate officer in the 150+ year history at Peoples Energy Company in Chicago.  He is an expert on hiring and promotion decisions and leadership development.  Over the course of his search career, he has interviewed thousands of leaders.  Please subscribe to the Leadership Lyceum: A CEO’s Virtual Mentor® in the podcast section at iTunes which will enable future content to come to you automatically. Rate us and spread the word among your fellow executives and board colleagues.  Program Disclaimer The only purpose of the podcast is to educate, inform and entertain. The information shared is based on the collection of experiences of each of the guests interviewed and should not be considered or substituted for professional advice. Guests who speak in this podcast express their own opinions, experience and conclusions, and neither The Leadership Lyceum LLC nor any company providing financial support endorses or opposes any particular content, recommendation or methodology discussed in this podcast. This podcast Leadership Lyceum: A CEO’s Virtual Mentor® has been a production of The Leadership Lyceum LLC. Copyright 2017. All rights reserved.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: QuintilesIMS, Teva Pharmaceutical Industries, Mylan, Novartis, Sandoz, Pfizer, Allergan, Sun Laboratories, Fresenius, Endo International, Lupin, Sanofi, Aspen Pharmacare, Aurobindo, Cipla, Apotex, Dr. Reddy's, Ypsomed.Persone: Alessandro Mostaccio (Movimento dei consumatori), Federico Spandonaro (Università Tor Vergata di Roma), Andrea Giustina (Università Vita e Salute San Raffaele), Annamaria Vezzani (Istituto Mario Negri di Milano), Pier Paolo di Fiore (IFOM), Sara Sigismund (Università Statale di Milano), Carlo Tacchetti (Ospedale San Raffaele di Milano), Giancarlo Agnelli (Università di Perugia), Andrea Fontanella (FADOI), Massimo Galli (Università degli Studi di Milano), François Houÿez (EURORDIS), Marco Romano (Chiltern International). Nuove terapie: elbasvir/grazoprevir.Patologie: allergie, diabete, epilessia, cancro, tromboembolismo, epatite C.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: QuintilesIMS, Teva Pharmaceutical Industries, Mylan, Novartis, Sandoz, Pfizer, Allergan, Sun Laboratories, Fresenius, Endo International, Lupin, Sanofi, Aspen Pharmacare, Aurobindo, Cipla, Apotex, Dr. Reddy's, Ypsomed.Persone: Alessandro Mostaccio (Movimento dei consumatori), Federico Spandonaro (Università Tor Vergata di Roma), Andrea Giustina (Università Vita e Salute San Raffaele), Annamaria Vezzani (Istituto Mario Negri di Milano), Pier Paolo di Fiore (IFOM), Sara Sigismund (Università Statale di Milano), Carlo Tacchetti (Ospedale San Raffaele di Milano), Giancarlo Agnelli (Università di Perugia), Andrea Fontanella (FADOI), Massimo Galli (Università degli Studi di Milano), François Houÿez (EURORDIS), Marco Romano (Chiltern International). Nuove terapie: elbasvir/grazoprevir.Patologie: allergie, diabete, epilessia, cancro, tromboembolismo, epatite C.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

The "Money Talks" experts answer listeners’ questions on DNP Select Income Fund and Teva Pharmaceutical Industries.

This week on "Money Talks", Principal Bil Lako, CFP®, and Director of Research Troy Harmon, CFA, CVA, discuss Trump’s proposed tax plan and the market’s moves during the week. The hosts delve into a case study about how simple mistakes in estate planning can cause trouble and cost your heirs time and money. The experts round out the show answering listeners’ questions on DNP Select Income Fund and Teva Pharmaceutical Industries.

1) A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington's Disease 2) What's Trending: Risk assessment in Duchenne dystrophy3) Topic of the Month: Neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 10, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Andrew McGarry about his paper on a randomized trial of coenzyme Q10 in Huntington Disease. Dr. Ted Burns talks with Dr. Sindhu Ramchandren about her Neurology: Genetics paper on Duchenne dystrophy for our “What's Trending” feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Gil Wolfe on myasthenia gravis. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. McGarry serves on an advisory board for Teva Pharmaceutical Industries, Ltd.; receives speaker honoraria for Teva Pharmaceutical Industries, Ltd. and ACADIA Pharmaceuticals, Inc.; and has received research support from Teva Pharmaceutical Industries, Ltd. and NINDS. Dr. Ramchandren received research support from the NIH.Dr. Wolfe advises for Grifols, Baxalta, Argenx, and UCB; receives speaker honoraria for Grifols and Baxalta; receives research support from CSL Behring; and serves as Associate Editor for Muscle and Nerve. Dr. Fullard reports no disclosures.

Jeremy Levin is chairman and CEO of Ovid Therapeutics, formerly president and CEO of Teva Pharmaceutical Industries, and former member of the executive committee at Bristol-Myers Squibb, where he led that company's 'string of pearls' strategy. His conversation with Nature Biotechnology covers shifting his mindset from treating patients to business development, his youth in South Africa, and how his past influences his view of the 2016 US presidential election results. See acast.com/privacy for privacy and opt-out information.

1) Optic nerve head component responses of multifocal electroretinogram in MS and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Beau Bruce interviews Drs. Teresa and Elliot Frohman about their paper on optic nerve head component responses of multifocal electroretinogram in MS. Dr. Adam Numis is reading our e-Pearl of the week about Terson's syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. John Trojanowski about progressive accumulation of tau pathology in patients with Alzheimer disease and how it occurred in a stereotypical manner. The participants had nothing to disclose except Drs. Bruce, Teresa Frohman, Eliot Frohman, Numis, Espay, and Trojanowski.Dr. Bruce is a consultant for Kaiser Permanente of Georgia for the CDC Vaccine Safety Datalink; receives research support from Novartis, Pfizer Inc, TEVA Pharmaceutical Industries, Ltd and the NIH; and was a recipient of the Practice Research Fellowship.Dr. Teresa Frohman serves as an editorial board member of National Multiple Sclerosis Society; is a consultant for Acorda, Novartis; serves on the speakers' bureau of Acorda Therapeutics, Inc., Novartis; receives royalties from the publication of Up-to-Date; received funding for travel from Acorda Therapeutics Inc., Novartis; received research support from the National Multiple Sclerosis Society and the NIH.Dr. Elliot Frohman is a consultant for TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics, Inc., Novartis, Genzyme Corporation, Abbott; serves on the speakers' bureau of TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis; receives royalties from the publication of Up-to-Date; and received funding for travel from TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Trojanowski serves as an Associate Editor for Alzheimer & Dementia; received research support from The Marian S. Ware Alzheimer Program, Benaroya and the NIH; holds 14 patents that may accrue revenue: US Patent 5,281,521, issued 25 Jan 1994: US Patent 5,580,898, issued 3 Dec 1996; US Patent 5,601,985, issued 11 Feb 1997; US Patent 5,733,734, issued 31 Mar 1998; US Patent 5,792,900, issued 11 Aug 1998; US Patent 5,849,988, issued 15 Dec 1998: US Patent 6,214,334, issued 10 Apr 2001; US Patent 6,358,681, issued 19 Mar 2002; US Patent 6,727,075, issued 27 Mar 2004; US Patent 7,011,827, issued 14 Mar 2006; Penn 0652, K1828, filed 5 Aug 1998; Penn L1986, Filed 13 Nov 1998; Penn R3868 (UPN-4439), filed 28 Feb 2005 and Penn S-4018, DB&R 46406- 217282, filed 22 Nov 2005: Treatment of Alzheimer's and Related Diseases with an Antibody and may accrue revenue in the future on patents submitted by the University of Pennsylvania as co-Inventor and received revenue from the sale of Avid to Eli Lilly and Company as co-inventor on imaging related patents submitted by the University of Pennsylvania while receiving research support from the NIH, Bristol-Myers Squibb, AstraZeneca and several non-profits.

1) Evidence-based guideline on periprocedural management of antithrombotic medications and neurovascular disease and 2) Topic of the month: Treatment of movement disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Melissa Armstrong about the guideline on periprocedural management of antithrombotic medications and neurovascular disease. Dr. Roy Strowd is reading our e-Pearl of the week about HINTS of stroke. In the next part of the podcast Dr. Binit Shah interviews Dr. Kapil Sethi about management of of non-dopa responsive axial motor symptoms. The participants had nothing to disclose except Drs. Armstrong, Strowd and Sethi.Dr. Armstrong serves on Neurology, Level of Evidence Review Team; received funding for a trip to the MDS International Congress; received research support from Abbott and was partially funded by a Edmond J. Safra Fellowship at Toronto Western Hospital.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Sethi serves on the scientific advisory board for International Essential Tremor Foundation; serves as an editorial board member of Neurology, Journal of Neuroscience, Medscape; is a consultant for Biogen Idec, GlaxoSmithKline, Novartis, Ipsen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Allergan, Inc; serves on the speakers' bureau of Biogen Idec, GlaxoSmithKline, Novartis, Ipsen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Allergan, Inc; received publishing royalties from Marcel Dekker Publisher; holds stock options in Elan Corporation and Pfizer Inc; involved in legal proceedings for welding litigation defense; receives research support from NPF center, Biogen Idec, GlaxoSmithKline, Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Acadia Pharmaceuticals, Inc. and NIH.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interview Drs. Pablo Martinez-Martin and K. Ray Chaudhuri about their paper on non-motor symptoms scale in Parkinson disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about varicella zoster virus can mimic Guillain-Barre syndrome. The podcast concludes where Dr. Ted Burns interviews Dr. David Loring for the Lesson of the Week on psychometric properties. The participants had nothing to disclose except Drs. Martinez-Martin and Chaudhuri. Dr. Martinez-Martin served on a scientific advisory board for Novartis; serves on the editorial boards of Neurologia, the Spanish Society of Neurology, Revista de Neurologia, and Societies of Neurology of the Spanish autonomous regions; has received speaker honoraria from Sanofi aventis and Novartis; and receives research support from Novartis and the Carlos III Institute of Health.Dr. Chaudhuri serves on scientific advisory boards for Solvay Pharmaceuticals, Inc., Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, and Teva Pharmaceutical Industries, Ltd.; has received speaker honoraria from the European Federation of Neurological Societies, the Swedish Movement Disorders Society, and LIMPE Italy; and receives research support for a clinical research nurse from UCB.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andrew Southerland interview Dr. Farid Abdo about his paper on ataxia-telangiectasia in adulthood. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the petite madelines phenomenon. The podcast concludes where Dr. Alberto Espay interviews Dr. Kapil Sethi for the Lesson of the Week (Toolbox) segment about paroxysmal movement disorders. The participants had nothing to disclose except for Drs. Espay and Sethi. Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.Dr. Sethi serves on the editorial advisory board of the Journal, Current Neurology Neuroscience Review; has received personal compensation as a consultant/speaker for GlaxoSmithKline; Biogen Idec; Novartis; Teva Pharmaceutical Industries, Ltd.; Allergan, Inc.; and Ipsen Pharmaceuticals Inc.; receives research support from Biogen Idec; GlaxoSmithKline; Teva Pharmaceutical Industries, Ltd.; Solvay Pharmaceuticals, Inc.; Novartis ACADIA Pharmaceuticals Inc. and the NIH [NET-PD PROGENI]; has served as an expert consultant in a legal proceeding and was Treasurer of the AAN Foundation.

On February 25, 2022, Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., McKesson Corp., Cardinal Health, Inc., and Amerisourcebergen Corp. announced that they had agreed to finalize a reported $26 billion settlement to resolve approximately 3,000 lawsuits from state and local governments regarding the opioid abuse crisis. The private plaintiffs' trial firms representing the counties and […]